leisure time -WSS

leisure time

author：entertainment 2025-10-02 21:00:30 - browse：1568

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Medicare reduced heart disease by changing how it pays doctors

hotspot

WSS

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

3 hurdles to bringing medical devices to the U.S. market

Impact of Dobbs ruling felt at reproductive medicine meeting

Will Ozempic

Eli Lilly expects to double planned employment in Boston center

FDA warns J&J's Abiomed: We will regulate your software

entertainment

leisure time

leisure time

Guidelines to prevent youth baseball injuries need more muscle

Why health workers in Gaza are injured or die at high rates

In Memoriam: Notable people who died in 2023

First Opinion Podcast: Long Covid needs a new approach

Hollywood unions extend contract negotiations for actors

Senate committee scrutinizes Medicare Advantage brokers

As demand for Covid shots wanes, Moderna seeks its next success

Medicare reduced heart disease by changing how it pays doctors

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Cloning humans is technically possible. It's curious no one has tried

leisure time

How climate

Why drug prescriptions should include diagnoses

STAT Readout Newsletter: Today's biggest biotech updates

Gene therapy has helped boys walk. Can scientists keep it that way?

Beam Therapeutics to lay off 20% of its staff, re

HHS leader on health, climate change and biopharma emissions

entertainment

hotspot

hotspot

leisure time